皮质类固醇注射与夜间夹板治疗腕管综合征的临床与成本效果:INSTINCTS试验
INSTINCTS试验是一项在初级保健机构开展的开放标签、平行组随机对照试验,纳入234例轻中度腕管综合征成人患者,比较单次皮质类固醇注射与夜间夹板的临床与成本效果。
要点
- 单次皮质类固醇注射在6周时改善轻中度腕管综合征症状优于夜间夹板。
- 两组均未报告不良事件,注射可作为初级保健中快速缓解症状的选择。
核心结论
- 单次皮质类固醇注射在6周时的临床效果优于夜间夹板,可作为初级保健中轻中度腕管综合征快速缓解症状的治疗选择。
研究设计与样本
- 随机、开放标签、实用性试验,从25个初级和社区肌肉骨骼诊所招募≥18岁、病程至少6周的轻中度特发性腕管综合征患者。
- 共234例参与者随机分配(夜间夹板组118例,皮质类固醇注射组116例),212例(91%)完成6周BCTQ评估。
主要发现
- 未报告不良事件。
临床怎么用
- 对于初级保健中就诊的轻中度腕管综合征患者,单次皮质类固醇注射可考虑作为快速缓解症状的优先选择。
局限性
- 研究为开放标签设计,患者和临床医生无法对干预设盲。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To our knowledge, the comparative effectiveness of commonly used conservative treatments for carpal tunnel syndrome has not been evaluated previously in primary care. We aimed to compare the clinical and cost-effectiveness of night splints with a corticosteroid injection with regards to reducing symptoms and improving hand function in patients with mild or moderate carpal tunnel syndrome. METHODS: We did this randomised, open-label, pragmatic trial in adults (≥18 years) with mild or moderate carpal tunnel syndrome recruited from 25 primary and community musculoskeletal clinics and services. Patients with a new episode of idiopathic mild or moderate carpal tunnel syndrome of at least 6 weeks' duration were eligible. We randomly assigned (1:1) patients (permutated blocks of two and four by site) with an online web or third party telephone service to receive either a single injection of 20 mg methylprednisolone acetate (from 40 mg/mL) or a night-resting splint to be worn for 6 weeks. Patients and clinicians could not be masked to the intervention. The primary outcome was the overall score of the Boston Carpal Tunnel Questionnaire (BCTQ) at 6 weeks. We used intention-to-treat analysis, with multiple imputation for missing data, which was concealed to treatment group allocation. The trial is registered with the European Clinical Trials Database, number 2013-001435-48, and ClinicalTrial.gov, number NCT02038452. FINDINGS: Between April 17, 2014, and Dec 31, 2016, 234 participants were randomly assigned (118 to the night splint group and 116 to the corticosteroid injection group), of whom 212 (91%) completed the BCTQ at 6 weeks. The BCTQ score was significantly better at 6 weeks in the corticosteroid injection group (mean 2·02 [SD 0·81]) than the night splint group (2·29 [0·75]; adjusted mean difference -0·32; 95% CI -0·48 to -0·16; p=0·0001). No adverse events were reported. INTERPRETATION: A single corticosteroid injection shows superior clinical effectiveness at 6 weeks compared with night-resting splints, making it the treatment of choice for rapid symptom response in mild or moderate carpal tunnel syndrome presenting in primary care. FUNDING: Arthritis Research UK.
引用
- Chesterton LS, Blagojevic-Bucknall M, Burton C, et al. The clinical and cost-effectiveness of corticosteroid injection versus night splints for carpal tunnel syndrome (INSTINCTS trial): an open-label, parallel group, randomised controlled trial. Lancet. 2018. PMID: 30343858. doi:10.1016/S0140-6736(18)31572-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。